Skip to main content
. 2020 Oct 15;30(4):426–434. doi: 10.1002/pds.5124

FIGURE 2.

FIGURE 2

Number of first‐time users of apixaban, dabigatran and rivaroxaban with NVAF by study year (July 2009 to June 2017). Data are from two clinical benefit providers (Salud Total and Compensar). NOAC, non‐vitamin K antagonist oral anticoagulant; NVAF, nonvalvular atrial fibrillation [Colour figure can be viewed at wileyonlinelibrary.com]